Emisphere Technologies discuses on high dose oral Eligen B12 1000mcg

Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that it is engaged in ongoing discussions with a potential licensee for its high dose oral Eligen^® B12 1000mcg as a Medical Food for individuals with B12 deficiency. In addition, the Company is evaluating other potential licensees as well as the possibility of marketing the product without a partner. A recently completed clinical trial showed that high dose Eligen^® B12 1000mcg can efficiently and quickly restore Vitamin B12 levels in deficient individuals compared to the current standard of care. "The process has been thorough but also time consuming. We want a commercial plan that will yield maximum value to our shareholders for this first important product, and at the same time provide flexibility for company growth and maximize value creation," said Michael V. Novinski, President and Chief Executive Officer of Emisphere Technologies, Inc.

The Company continues to evaluate potential financing opportunities to address its cash needs for ongoing operations and programs, including a potential equity financing.